Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31234416 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL2494729 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL18204848 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL2353368 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL12192438 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL15122945 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL15133204 | 0.89 | CHRM2 (0.32) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL20380929 | 0.87 | GLA (0.34) | NR1H2 | |
| SCHEMBL18612437 | 0.87 | GLA (0.34) | NR1H2 | |
| SCHEMBL5455578 | 0.86 | MAPT (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3447052-B1 | METHODS OF PREPARING NEW IDH1 INHIBITORS | LES LABORATOIRES SERVIER SAS (FR) | 2021-10-20 | — | — | EP | disclosed |
| EP-3497093-B1 | SULFONYL PYRIDYL TRP INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200339626-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2020-10-29 | — | — | US | disclosed |
| US-10717764-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10695348-B2 | Sulfonyl pyridyl TRP inhibitors | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20190315802-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2019-10-17 | — | — | US | disclosed |
| WO-2018029288-A1 | SULFONYL PYRIDYL TRP INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-02-15 | — | — | WO | disclosed |
| US-20170057994-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-03-02 | — | — | US | disclosed |
| US-8263549-B2 | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263549-B2 | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8030307-B2 | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease | ENANTA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030307-B2 | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease | ENANTA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20090180983-A1 | BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090175822-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090175822-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| WO-2009070692-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180983-A1 | BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE | PREP, PRSS1, PPIC | PTPN1 1280/4885NR1H2 2238/4885NR1H3 1763/4885 |
| US-20200339626-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | PTPN1 2350/4885NR1H2 3479/4885NR1H3 3324/4885 |
| US-10695348-B2 | Sulfonyl pyridyl TRP inhibitors | TRPA1, TRPV1, TRPV5 | PTPN1 550/4885NR1H2 2472/4885NR1H3 3371/4885 |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | PTPN1 2350/4885NR1H2 3479/4885NR1H3 3324/4885 |
| US-20090175822-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PREP, PRSS1, CTSC | PTPN1 1073/4885NR1H2 1798/4885NR1H3 1368/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | PTPN1 2070/4885NR1H2 1224/4885NR1H3 1840/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | PTPN1 2070/4885NR1H2 1224/4885NR1H3 1840/4885 |
| US-10717764-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | PTPN1 2350/4885NR1H2 3479/4885NR1H3 3324/4885 |
| US-20190315802-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | PTPN1 2350/4885NR1H2 3479/4885NR1H3 3324/4885 |
| US-20170057994-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | PTPN1 2350/4885NR1H2 3479/4885NR1H3 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.